Annovis Bio (NYSE: ANVS) widens losses as Phase 3 Alzheimer’s trial hits full enrollment
Rhea-AI Filing Summary
Annovis Bio, Inc. reported significantly higher operating losses for the quarter and six months ended June 30, 2026 while advancing its lead Alzheimer’s program. The company fully enrolled its pivotal Phase 3 trial in early Alzheimer’s disease with 850 patients and is planning an open-label extension to allow continued buntanetap treatment after trial completion. Topline data are targeted for early 2027, and preparations for a potential regulatory submission have begun.
For the quarter, operating expenses rose to $14.4 million from $6.3 million a year earlier, driven by research and development of $12.0 million versus $5.2 million. Net loss widened to $14.8 million from $6.2 million, and to $32.4 million for the first half of 2026 from $11.8 million. The balance sheet showed cash and cash equivalents of $18.7 million and a large increase in warrant liability to $19.9 million, resulting in negative stockholders’ equity of $(4.3) million as of June 30, 2026.
Positive
- Phase 3 AD trial fully enrolled with 850 patients, a key milestone that supports the development path for buntanetap and enables topline data readout planned for early 2027.
- Preparations for regulatory submission are already underway ahead of the planned early 2027 topline data, indicating active planning for a potential marketing application if results are favorable.
Negative
- Net loss increased to $14.8 million in Q2 2026 from $6.2 million a year earlier, reflecting much higher research and development and general and administrative spending.
- Six‑month net loss rose to $32.4 million from $11.8 million, more than doubling year over year as clinical development spending accelerated.
- Stockholders’ equity turned negative to $(4.3) million at June 30, 2026, compared with positive $16.9 million at year‑end 2025, driven in part by a higher warrant liability.
- Warrant liability increased to $19.9 million from $0.6 million at December 31, 2025, materially raising reported total liabilities relative to assets.
Filing Explained
The August 14 8-K reports Annovis Bio’s unaudited second-quarter results; its key additional structural disclosure is that common shares issued and outstanding rose to 42,606,152 at June 30, 2026 from 27,199,139 at December 31, 2025, reducing the percentage of the company represented by any unchanged existing holding.
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Net loss Q2 2026: $14,820,815
Net loss six months 2026: $32,427,198
R&D expense Q2 2026: $12,007,300
+4 more
7 metrics
Net loss Q2 2026
$14,820,815
Three months ended June 30, 2026
Net loss six months 2026
$32,427,198
Six months ended June 30, 2026
R&D expense Q2 2026
$12,007,300
Three months ended June 30, 2026
Cash and cash equivalents
$18,728,945
As of June 30, 2026
Warrant liability
$19,933,000
As of June 30, 2026
Stockholders’ equity
$(4,254,619)
As of June 30, 2026
Phase 3 AD trial enrollment
850 patients
Pivotal early Alzheimer’s disease study
Key Terms
warrant liability, open-label extension, Phase 3 clinical-stage, accumulated deficit, +1 more
5 terms
warrant liability financial
"Non-current liabilities: Warrant liability 19,933,000"
Warrant liability is the financial obligation a company records when it grants warrants—special options giving the holder the right to buy company shares at a set price in the future. It matters to investors because changes in this liability can affect a company's reported earnings and overall financial health, similar to how a pending contract can influence a company's future value.
open-label extension medical
"continue the ongoing study with an open-label extension (OLE)"
An open-label extension is a continuation of a clinical trial where all participants and researchers know which treatment is being given, often after an initial blinded phase. It allows further study of a drug's long-term safety and effectiveness. For investors, it can indicate ongoing interest and confidence in a product's potential, influencing perceptions of its future value.
Phase 3 clinical-stage medical
"a Phase 3 clinical-stage biotechnology company developing"
accumulated deficit financial
"Accumulated deficit (196,130,857)"
Accumulated deficit is the running total of a company’s past net losses minus any profits, showing how much the business has eaten into its own funds over time—think of it like a bank account that’s been overdrawn by repeated shortfalls. It matters to investors because a large accumulated deficit reduces the cushion that protects owners and creditors, can limit dividends or borrowing, and signals how much funding the company may need to reach profitability.
additional paid-in capital financial
"Additional paid-in capital 191,871,978"
Amount of money shareholders have paid to a company for shares that is above the stock’s nominal or par value; think of it as the extra premium paid when a group buys a ticket that has a low listed price. It matters to investors because it represents permanent capital on the balance sheet that can cushion losses, affect book value per share and indicate how much fresh cash equity holders have contributed beyond the minimum share value.
Earnings Snapshot
Net loss Q2 2026: $14,820,815
quarter and six months ended June 30, 2026
Net loss Q2 2026
$14,820,815
higher than $6,220,058 in Q2 2025
Net loss six months 2026
$32,427,198
higher than $11,757,127 in the first half of 2025
R&D expense Q2 2026
$12,007,300
higher than $5,161,921 in Q2 2025
Cash and cash equivalents
$18,728,945
slightly lower than $19,532,338 at December 31, 2025
FAQ
What clinical milestone did Annovis Bio (ANVS) reach in its Alzheimer’s program?
Annovis Bio reached full enrollment of 850 patients in its pivotal Phase 3 trial in early Alzheimer’s disease. The company also plans an open-label extension so patients can continue buntanetap treatment after completing the blinded study.
When does Annovis Bio (ANVS) expect topline data from its Phase 3 Alzheimer’s trial?
Annovis Bio expects topline data from its pivotal Phase 3 early Alzheimer’s study in early 2027. The company states it has already begun preparing for a regulatory submission so it can move quickly once results are available.
How did Annovis Bio’s (ANVS) net loss change in Q2 2026 versus Q2 2025?
Net loss for Q2 2026 was $14.8 million, compared with $6.2 million in Q2 2025. The wider loss reflects higher research and development expenses and increased general and administrative costs tied to advancing clinical programs.
What was Annovis Bio’s (ANVS) cash position as of June 30, 2026?
As of June 30, 2026, Annovis Bio reported $18.7 million in cash and cash equivalents. This compares with $19.5 million at December 31, 2025, indicating modest cash usage through the first half of 2026 as development spending increased.
Why did Annovis Bio (ANVS) report negative stockholders’ equity at June 30, 2026?
Stockholders’ equity was $(4.3) million at June 30, 2026, versus $16.9 million at year‑end 2025. The shift reflects the accumulated deficit of $196.1 million and a sharp rise in warrant liability that together pushed liabilities above total assets.
How much did Annovis Bio (ANVS) spend on R&D in Q2 and the first half of 2026?
Research and development expense was $12.0 million in Q2 2026, up from $5.2 million a year earlier, and $28.7 million for the first half of 2026, compared with $10.2 million in the prior‑year period, reflecting intensified clinical activity.
AI-generated analysis. How Rhea-AI works. Not financial advice.
